Neurological Presentations in Patients with COVID-19 in Cytokine Storm

Gorkem Tutar Gursoy1, Hatice Yuksel1, Inci Mulkem Simsek1, Saniye Oral1, Fadime Erdogan Kucukdagli1, Ayberk Karaman3, Esragul Akinci2, Aliye Bastug2, Hatice Rahmet Guner2 and Hesna Bektas1

1Department of Neurology, Ankara City Hospital, Cankaya, Turkey, 2Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Cankaya, Turkey and 3Department of Neurosurgery, Ankara City Hospital, Cankaya, Turkey

Abstract: Background: Coronavirus disease 2019 (COVID-19) infection causes a wide variety of neurological disorders by affecting both central and peripheral nervous systems. The cytokine storm (CS) has been blamed for the development of severe neurological disorders in COVID-19. However, the relationship between COVID-19 CS and neurological manifestations has not been adequately studied. Thus, we aimed to investigate the neurological presentations in patients with COVID-19 CS. Methods: The study population consisted of hospitalized moderate-to-severe COVID-19 patients. It was divided into two groups CS (36 patients, 29.3%) and non-CS (87 patients, 70.7%) based on significant clinical symptoms, elevated inflammatory marker levels, radiological findings, and interleukin-6 levels (IL-6). Results: The three most common neurological symptoms in the CS group were altered level of consciousness, headache, and unsteadiness. Altered level of consciousness was higher in the CS group (69.4%) than the non-CS group (25.3%) (p<0.001). The frequency of headache was comparable in both groups (p=0.186). The number of patients requiring intensive care unit and intubation was higher in the CS group (p=0.005 and p=0.001). The mortality rate in the CS group (38.9%) was higher than the non-CS group (8.0%) (p<0.001). IL-6, CRP, ferritin, neutrophil-lymphocyte ratio, procalcitonin, and D-dimer levels were higher in the CS group for all (p<0.001) while lymphocyte count was lower (p=0.003). Conclusion: The most common neurological presentation in patients with CS was altered level of consciousness. The presence of CS was an independent risk factor for high mortality.

RéSUMÉ : Symptômes neurologiques chez des patients atteints d’une infection à la COVID-19 et victimes d’une tempête de cytokines Contexte : Les infections à la COVID-19 peuvent provoquer une grande variété de troubles neurologiques en affectant le système nerveux central et le système périphérique. Les tempêtes de cytokines (TC) ont ainsi été mises en cause dans le développement de graves troubles neurologiques liés aux infections à la COVID-19. Cela dit, l’association entre ces infections (et les TC) et des symptômes d’atteinte neurologique n’a pas encore été étudiée de façon adéquate. Voilà pourquoi nous entendons nous pencher sur de tels symptômes chez des patients atteints d’une infection à la COVID-19 qui ont été victimes d’une TC. Méthodes : La cohorte étudiée était composée de patients atteints d’une infection à la COVID-19 modérée à sévère ayant été hospitalisés. Elle a été divisée en deux sous-cohortes sur la base de symptômes cliniques significatifs, de taux élevés de marqueurs inflammatoires, de résultats radiologiques et de taux d’interleukine-6 (IL-6) : d’une part, une sous-cohorte de 36 patients victimes d’une TC (29,3 %) et, d’autre part, une autre regroupant 87 autres patients ayant été épargnés par ce phénomène (70,7 %). Résultats : Les trois symptômes neurologiques les plus fréquents dans la première sous-cohorte étaient une altération des niveaux de conscience, des maux de tête et un déséquilibre. Des niveaux de conscience altérés se sont ainsi révélés plus élevés au sein de la sous-cohorte des patients victimes d’une TC (69,4 %) qu’au sein de l’autre sous-cohorte (25,3 %) (p = 0,001). La fréquence des maux de tête s’est quant à elle avérée comparable d’une sous-cohorte à l’autre (p = 0,186). Soulignons que le nombre de patients nécessitant des soins intensifs et l’intubation était plus élevé dans la première sous-cohorte (p = 0,005 et p = 0,001). Le taux de mortalité dans cette dernière (38,9 %) était également plus élevé que dans la deuxième sous-cohorte (8,0 %) (p = 0,001). Enfin, les taux d’IL-6, de protéine C réactive (PCR), de ferrítine, de procalcitonine (PCT) et de D-dimères, de même que le rapport neutrophiles-lymphocytes, étaient plus élevés dans la première sous-cohorte (tous les p = 0,001) tandis que la numération lymphocytaire était plus faible (p = 0,003). Conclusion : Le symptôme neurologique le plus courant chez les patients victimes d’une TC était une altération du niveau de conscience. Le fait d’être victime d’un tel choc inflammatoire a aussi été identifié comme un facteur de risque indépendant de mortalité élevée.

Keywords: COVID-19; Cytokine storm; Neurological disorders; Altered level of consciousness; Interleukin-6

© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the deaths of millions of people since it was declared a pandemic by the World Health Organization. Although COVID-19 primarily invades the respiratory system, it often tends to spread in various organ systems. As a part of many organ system involvements, COVID-19 also causes serious disorders related to both the central and peripheral nervous systems. However, the pathogenesis of neurological involvement has not been clearly demonstrated. Recently, neurological system involvement has been partially attributed to cytokine storm (CS).

CS is an inclusive term describing various disorders with hyperinflammation and multiorgan involvement characterized by excessive cytokine release resulting from an exaggerated immune activation. CS can occur during the course of autoimmune diseases, malignancies, and various infectious diseases such as SARS, MERS, and H5N1 influenza.

Excessive increases in levels of cytokines such as interleukin-1β, interleukin-6 (IL-6), IP-10, IL-2R, tumor necrosis factor-α, and interferon-γ have been shown in CS. However, their role in the pathogenesis of CS has not been fully elucidated. Recently, IL-6, a cytokine secreted by immune and stromal cells, has become a focus of interest in COVID-19 CS. It is a proinflammatory cytokine and plays a key role in CS by amplifying the immune response. The level of IL-6 elevation correlates with the need for mechanical ventilation and increased mortality.

Accumulating data suggest that a subset of severe COVID-19 patients has CS. However, the exact criteria for the diagnosis of COVID-19 CS have not yet been established. Caricchio et al. described some predictive criteria for the diagnosis of COVID-19-associated CS in their well-designed study. It was called the Temple Criteria. However, they did not use any cytokine level as a criterion (Figure 1).

In this study, we aimed to investigate the neurological presentations in patients with COVID-19 CS by using modified Temple criteria.

Patients and Methods

This prospective study was conducted in Ankara City Hospital. One hundred fifty patients under care in COVID-19 intensive care units and floors were enrolled in the study.

We recorded patients’ information, including age, gender, medical comorbidities, and neurological comorbidities. Laboratory tests including IL-6, CRP, ferritin, procalcitonin, D-dimer, fibrinogen, troponin I, complete blood count, creatinine, liver function tests, and creatine kinase were studied. A polymerase chain reaction (RT-PCR) test for COVID-19 from nasopharyngeal swab was studied. All patients had chest computed tomography.

Patients’ neurological symptoms including headache, altered level of consciousness, seizures, vertigo, unsteadiness, anosmia/hyposmia, dysgeusia, nausea, paresthesia, tinnitus, and sleep disorders were obtained by trained neurologists from the patients or their relatives and medical notes (recorded during hospital follow-up prospectively). Altered level of consciousness was defined as changes in consciousness such as somnolence, agitation, delirium, confusion, and coma. The evaluation of unsteadiness, which is defined as difficulty in standing and inability to maintain body balance, was performed when the patients’ consciousness level was normal.

The patients’ clinical, laboratory, and radiological data were evaluated by a team consisting of trained neurology and infectious diseases physicians. “Confirmed cases” with SARS-CoV-2 infection detected by RT-PCR test of a nasopharyngeal sample or confirmed antibody test were included. In addition, “probable cases” of SARS-CoV-2 infection with severe respiratory disease with clinical and radiographic evidence of pneumonia despite a negative RT-PCR or antibody testing were included in the study. Twenty-seven patients with negative RT-PCR tests were excluded from the study because their radiological images were not typical for COVID-19.

COVID-19 CS is defined as a state of hyperinflammation characterized by excessive cytokine release in a subset of patients with COVID-19. To date, no valid criteria have been defined for the COVID-19 CS. For the first time, Caricchio et al. established criteria to define COVID-19 CS. Their criteria were based on the presence of COVID-19 symptoms, ground-glass opacities (GGO) detected on lung images, elevated CRP, and ferritin levels accompanied by some abnormal biochemical and hematological parameters. In the identification of patients with CS, we used some criteria defined by Caricchio et al. and also IL-6 levels as an additional criterion. IL-6 is recognized as a key cytokine driving the hyperinflammatory state in COVID-19 CS. Therefore, we thought it would be beneficial to add IL-6 level as a criterion to the COVID-19 CS criteria. There has no generally accepted cut-off value of IL-6 for the diagnosis of CS in COVID-19 infection. However, a tenfold high level of IL-6 was found to be associated with the severity of the disease. Therefore, we considered IL-6 levels 10 times higher than normal detected in two blood samples taken 3 days apart from the patients as an indicator of ongoing excessive cytokine release and used it as an additional criterion for CS.

Thirty-six patients (29.3%) were included in the CS group based on the criteria of prominent clinical symptoms (cough, fever, respiratory distress, and so forth), high inflammatory marker levels (CRP > 4.6 mg/dL and ferritin > 250 ng/mL), typical radiological findings (bilateral GGO in the lungs), and high cytokine level (IL-6 levels > 10 times than normal detected in two blood samples taken 3 days apart). The remaining 87 patients (70.7%) were enrolled in the non-CS group.

The study was approved by the local ethical committee (Ankara City Hospital Ethics Committee).

All statistical analyses were done using IBM SPSS statistic 22.0 (Chicago, IL, USA). Data were expressed as mean ± SD. Continuous variables were compared using the Mann–Whitney U-test. Categorical variables were compared using the chi-square test. Binary logistic regression analysis was performed to detect independent factors associated with altered level of consciousness and mortality. A p-value < 0.05 was considered statistically significant.

Results

The mean age in the CS group was higher than in the non-CS group (p=0.003). The CS group included more males than the non-CS group (p=0.027). RT-PCR positive for COVID-19 was similar in both groups (p=0.254) (Table 1).

The neurological and medical comorbidities in the CS and non-CS groups are presented in Table 1. Although the presence of neurological comorbidity was more frequent in the CS group than in the non-CS group, the difference was not significant (p=0.186). The
presence of medical comorbidity was similar in both groups (p=0.400) (Table 1).

IL-6, CRP, ferritin, NLR, neutrophil count, procalcitonin, D-dimer, troponin I, creatinine, AST, LDH, and CK level were higher in the CS group than non-CS group (p=0.001, p=0.001, p=0.00, p=0.046, p=0.001, p=0.018, p=0.008, p=0.010, p=0.001, and p=0.003, respectively) while lymphocyte count was lower (p=0.003) (Table 2).

The number of patients requiring intensive care unit and intubation was higher in the CS group than in the non-CS group (p=0.005 and p=0.001). Mortality rate in the CS group (38.9%) was higher than in the non-CS group (8.0%) (p=0.001) (Table 3).

The three most common neurological symptoms in CS group were altered level of consciousness, headache, and unsteadiness. While the frequency of headache was the same in both groups (p=0.186), altered level of consciousness was higher in the CS group (69.4%) than the non-CS group (25.3%) (p=0.001). Although the frequency of unsteadiness in the CS group (30.6%) was higher than in the non-CS group (18.4%), there were no significant differences (p=0.138). Ischemic stroke was observed more frequently than hemorrhagic stroke in both groups; however, there was no difference between the two groups regarding the frequency of ischemic stroke (p=0.638). There was no difference between the two groups in terms of the frequency of all other neurological disorders (Table 3).

In binary logistic regression analysis, CS and neurological comorbidity were determined as an independent risk factor for altered level of consciousness. CS and age were detected as independent risk factors for mortality (Table 4).

**Discussion**

We demonstrated that the most common neurological disorder in patients with COVID-19 CS is altered level of consciousness. CS was associated with increased need for intensive care and a high mortality rate. CS and age were independent risk factors for mortality in COVID-19 patients. In COVID-19 patients without CS,
### Table 1: Comparison of the demographic data of patients with and without cytokine storm

|                          | Non-cytokine storm group | Cytokine storm group | p   |
|--------------------------|--------------------------|----------------------|-----|
| Age (years)              | 59.67 ± 13.66            | 67.52 ± 10.89        | 0.003|
| Gender Female/Male       | 43 (49.4%)/44 (50.6%)    | 10(27.8%)/26 (72.2%) | 0.027|
| RT-PCR for COVID-19      |                          |                      |     |
| Positive                 | 67 (68.4%)               | 31 (86.1%)           | 0.254|
| Negative                 | 20 (23.0%)               | 5 (13.9%)            |     |
| Medical comorbidity      | 56 (64.4%)               | 26 (72.2%)           | 0.400|
| Coronary artery disease  | 14 (16.1%)               | 12 (33.3%)           | 0.033|
| Arrhythmia               | 5 (5.2%)                 | -                    | 0.142|
| Hypertension             | 44 (50.6%)               | 21 (58.3%)           | 0.433|
| Hyperlipidemia           | 12 (13.8%)               | 5 (13.9%)            | 0.989|
| Diabetes mellitus        | 25 (28.7%)               | 12 (33.3%)           | 0.613|
| Chronic pulmonary disease| 8 (9.2%)                 | 7 (19.4%)            | 0.114|
| Chronic renal failure    | 2 (2.3%)                 | 3 (8.3%)             | 0.123|
| Neurological comorbidity | 15 (17.2%)               | 10 (27.8%)           | 0.186|
| Cerebrovascular accident | 11 (12.6%)               | 4 (11.1%)            | 0.813|
| Dementia                 | 4 (4.6%)                 | 4 (11.1%)            | 0.231|
| Epilepsy                 | 4 (4.2%)                 | -                    | 0.575|
| Parkinson disease        | 1 (1.1%)                 | 1 (2.8%)             | 0.501|

If a p value is < 0.05, it was written in bold to emphasize.

### Table 2: Comparison of the laboratory data of patients with and without cytokine storm

|                          | Non-cytokine storm group | Cytokine storm group | p   |
|--------------------------|--------------------------|----------------------|-----|
| Interleukine-6 (pg/mL) (1. measurement) | 30.70 ± 35.48           | 122.85 ± 163.44     | 0.001|
| Interleukine-6 (pg/mL) (2. measurement) | 117.44 ± 248.69         | 570.80 ± 432.78     | 0.001|
| C-reactive protein (mg/dL) | 10.68 ± 9.09            | 17.31 ± 10.37       | 0.001|
| Ferritin (ng/mL)         | 572.63 ± 554.98          | 2882.86 ± 7069.34   | 0.001|
| Neutrophil-lymphocyte ratio | 8.49 ± 20.79            | 10.78 ± 10.76       | 0.001|
| Neutrophil (10⁹/L)       | 6.79 ± 11.94             | 7.53 ± 7.03         | 0.046|
| Lymphocyte (10⁹/L)       | 1.56 ± 2.32              | 0.87 ± 0.44         | 0.003|
| Hemoglobin (g/dL)        | 13.08 ± 1.49             | 12.56 ± 1.99        | 0.503|
| Platelets (10⁹/L)        | 259.56 ± 121.47          | 247.02 ± 108.45     | 0.691|
| Procalcitonin (μg/L)     | 0.17 ± 0.39              | 4.19 ± 14.17        | 0.001|
| D-dimer (mg/dL)          | 1.47 ± 2.64              | 8.21 ± 13.44        | 0.001|
| Fibrinogen (g/L)         | 5.28 ± 1.77              | 5.62 ± 1.94         | 0.231|
| Troponin I (ng/L)        | 12.31 ± 26.95            | 215.75 ± 711.97     | 0.018|
| Creatinine (mg/dL)       | 0.81 ± 0.27              | 1.34 ± 1.31         | 0.008|
| Alanine aminotransferase (U/L) | 48.49 ± 60.07       | 163.61 ± 524.46     | 0.123|
| Aspartate aminotransferase (U/L) | 52.80 ± 75.44     | 439.22 ± 1596.71    | 0.010|
| Lactate dehydrogenase (U/L) | 343.13 ± 125.82        | 1006.80 ± 2164.36   | 0.001|
| Creatine kinase (U/L)    | 215.77 ± 469.82          | 617.08 ± 912.03     | 0.003|

If a p value is < 0.05, it was written in bold to emphasize.
The most common neurological symptom was headache. Their mortality rate was also very low compared to those with CS. COVID-19 affects both the peripheral and central nervous system (CNS) intensely as well as other organ systems. It can cause a wide range of problems in patients, from mild symptoms such as headache and loss of smell to severe symptoms such as impaired consciousness and epileptic seizures. While it causes mild neurological symptoms in most patients, the underlying pathogenesis of why it causes severe neurological disorders in a subgroup of patients is not fully known.

The results of recent studies suggest that CS may be responsible for the severe involvement seen in both the neurological and other systems in COVID-19. CS may occur during the course of infections, neoplastic, and autoimmune diseases. This hypercytokine-mic inflammation may be responsible for end-organ damage. Well-established criteria are available for the determination of two CS forms containing hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). Although some findings of CS in COVID-19 are similar to CS in HLH and MAS, it has unique features different from them. Caricchio et al. showed that the criteria defined for HLH and MAS were not useful in the diagnosis of COVID-19 CS. The exact criteria for the diagnosis of COVID-19 CS have not yet been clarified. Therefore, a limited number of studies in the literature provide information about the neurological involvement in patients with COVID-19 CS. Although previous studies revealed a high frequency of impaired consciousness in severe COVID-19 infection, its frequency in COVID-19 CS has not been reported before. Our study revealed a very high frequency of altered level of consciousness (69.4%) in patients with CS. Impaired consciousness in COVID-19 occurs as a result of factors such as metabolic-toxic, hypoxic, cerebrovascular events, and medications. Direct invasion of the CNS by the virus has also been implicated as a cause of neurological symptoms in COVID-19. Consistent with this mechanism, SARS-CoV-2 was detected in brain specimens in an autopsy series involving 22 patients.

| Table 3: Comparison of the clinic data of patients with and without cytokine storm |
|---------------------------------|-----------------|-----------------|-------|
|                                | Non-cytokine storm group n=87 | Cytokine storm group n=36 | p     |
| Intensive care unit            | 36 (41.4%)       | 25 (69.4%)       | 0.005 |
| Intubation                      | 11 (12.6%)       | 14 (38.9%)       | 0.001 |
| Mortality                       | 7 (8.0%)         | 14 (38.9%)       | 0.001 |

| Neurological presentations     |                  |                  |       |
| Altered level of consciousness | 22 (25.3%)       | 25 (69.4%)       | 0.001 |
| Headache                       | 57 (65.5%)       | 19 (52.8%)       | 0.186 |
| Seizure                        | 4 (4.6%)         | 3 (8.3%)         | 0.416 |
| Dizziness                      | 29 (33.3%)       | 9 (25.0%)        | 0.363 |
| Vertigo                        | 26 (29.9%)       | 6 (16.7%)        | 0.128 |
| Unsteadiness                   | 16 (18.4%)       | 11 (30.6%)       | 0.138 |
| Anosmia/Hyposmia               | 9 (10.3%)        | 3 (8.3%)         | 0.732 |
| Dysgeusia                      | 19 (10.3%)       | 6 (16.7%)        | 0.369 |
| Nausea                         | 25 (28.7%)       | 9 (25.0%)        | 0.673 |
| Paresthesia                    | 12 (13.8%)       | 54 (13.9%)       | 0.989 |
| Tinnitus                       | 3 (3.4%)         | –                | 0.555 |
| Sleep disorders                | 11 (12.6%)       | 4 (11.1%)        | 0.813 |
| Ischemic stroke                | 11 (12.6%)       | 4 (11.1%)        | 0.813 |
| Hemorrhagic stroke             | 2 (2.3%)         | –                | 0.359 |
| Cerebral vein thrombosis       | 1 (1.1%)         | –                | 0.518 |

If a p value is < 0.05, it was written in bold to emphasize.

| Table 4: Independent factors associated with altered level of consciousness and mortality in binary logistic regression analysis |
|--------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                          |
|                                                                                                                          |
|                                                                                                                          |
| Altered level of consciousness                                                                                           |
| p value | Exp(B) | %95 Confidence interval |
| Age                                      | 0.901 | 1.002 | 0.966–1.040 |
| Gender                                   | 0.316 | 1.570 | 0.651–3.787 |
| Cytokine storm                           | 0.001 | 6.059 | 2.363–15.522 |
| Neurological comorbidity                 | 0.038 | 3.087 | 1.065–8.951 |
| Medical comorbidity                      | 0.083 | 2.413 | 0.891–6.536 |
|                                                                                                                          |
| Mortality                                                                                                               |
| p value | Exp(B) | %95 Confidence interval |
| Age                                      | 0.019 | 1.067 | 1.011–1.126 |
| Gender                                   | 0.622 | 1.333 | 0.425–4.175 |
| Cytokine storm                           | 0.003 | 5.260 | 1.778–15.556 |
| Neurological comorbidity                 | 0.666 | 0.755 | 0.211–2.698 |
| Medical comorbidity                      | 0.402 | 1.739 | 0.477–6.342 |

If a p value is < 0.05, it was written in bold to emphasize.
series involving 43 patients, neuroimmune activation was detected in all brain specimens examined. The authors showed that there was no correlation between the severity of neuroimmune activation and the presence of SARS-CoV-2 in the brain specimens. They stated that the detected neuropathological changes may be due to other factors such as CS and neuroimmune stimulation rather than direct invasion of the virus into the CNS. In a recent study, increased levels of cytokines in cerebrospinal fluid have been demonstrated in COVID-19 patients with encephalitis. Thus, one of the reasons for impaired consciousness in COVID-19 may be the direct effect of increased cytokine levels on the CNS.

SARS-CoV-2 has been shown to cause endothelitis, which might explain the increased rate of thrombosis in various organs. In addition, cytokines can cause significant endothelial damage. Also, proinflammatory cytokines, including IL-6, activate the coagulation system and inhibit the anticoagulant pathway. Therefore, there is a hypercoagulable condition in COVID-19 patients with and without CS. Pathology studies have shown an increased incidence of microthrombi in patients with severe COVID-19. However, microthrombi may not be demonstrated on radiological images. For this reason, our study design was insufficient to demonstrate and compare the exact frequency of microangiopathic thrombus in patients with and without CS. Consequently, we cannot exclude the possibility that one of the underlying causes of the impaired consciousness’ high frequency in our CS patients may be cytokine-induced microthrombosis.

Hemorrhagic stroke is a rare complication of COVID-19. The results of our study were consistent with the literature. While hemorrhagic stroke was not detected in any patient with CS, it was detected in only two patients without CS.

One of the most common complaints in COVID-19 patients is a headache. The frequency of headache in hospitalized patients with COVID-19 has been reported to be 13%–34%. Stimulation of peripheral trigeminal nerve endings by factors such as direct invasion of the virus, hypoxia, and pro-inflammatory cytokines is blamed for the occurrence of headache, but the exact mechanism is still unknown. Although the occurrence of headache in COVID-19 is attributed to CS, a direct connection has not been established. We also did not find a causal relationship between headache and CS. In our study, while headache was the second most common symptom in patients with CS, it was the most common symptom in patients without CS. Since we asked our patients about their headaches as a part of standard questioning, reporting mild headaches by patients may explain the high frequency of headaches in our study group.

Epileptic seizure frequency has been reported between 1.6% and 4% in COVID-19. Although there is no defined mechanism, CS has also been associated with the occurrence of seizures. Increased IL-6 levels have been associated with the development of seizures. We found a higher frequency of seizures in patients with CS. Due to the small number of our study population, that result may not be generalized.

Our study suggests that CS does not have a significant effect on some neurological presentations such as dysgeusia, anosmia, nausea, and dizziness. However, considering the limited data in our study, large and detailed studies are needed to clearly define the relationship between them.

As discussed above, IL-6 elevation also has been demonstrated in severe neurological involvement as in other organ systems affected by hypercytokinemic inflammation. This excess IL-6 release can play a major role in the pathogenesis or simply be an epiphenomenon of other cytokine releases. As a result, IL-6 stands out as an important cornerstone indicating serious organ involvement in CS. Therefore, the addition of cytokines, especially IL-6, as a criterion in the diagnosis of CS, may help in establishing an accurate diagnosis.

To our knowledge, our study is the first to present neurological findings specifically in COVID-19 CS, although it is difficult to follow the rapidly growing number of COVID-19 related studies. The limitation of our study is that only one cytokine (IL-6) was studied to define COVID-19 CS. Another limitation of our study is that assessment of consciousness level may have subjectivity in the acute care settings.

In conclusion, we detected CS in approximately one-third of hospitalized moderate-severe COVID-19 patients. Altered level of consciousness was the most common neurological complication in patients with CS. Also, the presence of CS was an independent risk factor for its high mortality rate.

Conflict of Interest. None.

Statement of Authorship. GTG: study design, data curation, statistical analysis, and drafting the manuscript; HY: study design, statistical analysis, and drafting the manuscript; IMS, SO, AK, FEK, and EA: data curation and drafting the manuscript; RG: study design and study supervision; HB: critical revision of the manuscript for intellectual content, study supervision.

References

1. Kim H-J, Hwang H, Hong H, Yim J-J, Lee J. A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic. Sci Rep. 2021;11:9784. DOI 10.1038/s41598-021-89182-8.
2. Whitaker A, Anson M, Harky A. Neurological manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand. 2020;142:14–22. DOI 10.1111/ane.13266.
3. Pilotto A, Masiocchi S, Volonghi I, et al. SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021;73:e3019–e3026. DOI 10.1093/cid/ciaa1933.
4. Thepmankorn P, Bach J, Lasfar A, et al. Cytokine storm induced by SARS-CoV-2 infection: the spectrum of its neurological manifestations. Cytokine. 2021;138:155404. DOI 10.1016/j.cytobio.2020.155404.
5. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–73. DOI 10.1056/NEJMra2026131.
6. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72:1059–63. DOI 10.1002/art.41285.
7. Amiques I, Pearlman AH, Patel A, et al. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol. 2020;16:1185–204. DOI 10.1080/1744666X.2021.1847084.
8. Copaeescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020;146:518–34.e1. DOI 10.1016/j.jaci.2020.07.001.
9. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020;217:e20200678. DOI 10.1084/jem.20200678.
10. Caricchio R, Gallucci M, Dass C, et al. Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis. 2021;80:88–95. DOI 10.1136/annrheumdis-2020-218323.
11. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395:1033–34. DOI 10.1016/S0140-6736(20)30628-0.
12. Nigrovic PA. COVID-19 cytokine storm: what is in a name? Ann Rheum Dis. 2021;80:3–5. DOI 10.1136/annrheumdis-2020-219448.

13. WHO COVID-19 Case definition; 2021. Available at: https://www.who.int/publications-detail/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2; accessed September 26, 2021.

14. Meanwathana J, Majam T. Interleukin-6 antagonists: lessons from cytokine release syndrome to the therapeutic application in severe COVID-19 infection. J Pharm Pract. 2021. DOI 10.1177/08971900211000691.

15. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Intensive Care Crit Care Med. 2020;30:1–9. DOI 10.1101/2020.03.30.20048058.

16. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92:791–96. DOI 10.1002/jmv.25770.

17. Liu T, Zhang J, Yang Y, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. Infect Dis. 2020. DOI 10.1101/2020.03.01.20029769.

18. Yuksel H, Gursoy GT, Dirik EB, et al. Neurological manifestations of COVID-19 in confirmed and probable cases: a descriptive study from a large tertiary care center. J Clin Neurosci. 2021;86:97–102. DOI 10.1016/j.jocn.2021.01.002.

19. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J Mol Hist. 2020;51:613–28. DOI 10.1007/s10735-020-09915-3.

20. Jarrahi A, Ahluwalia M, Khodadadi H, et al. Neurological consequences of COVID-19: what have we learned and where do we go from here? J Neuroinflammation. 2020;17:286. DOI 10.1186/s12974-020-01957-4.

21. Tyson B, Erdodi L, Ray S, Agarwal P. Altered mental status in 71 deaths due to COVID-19. Int J Neurosci. 2020. DOI 10.1080/00207454.2020.1825422.

22. Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16–27.e1. DOI 10.1016/j.cell.2020.08.028.

23. Ahmed MU, Hanif M, Ali MI, et al. Neurological manifestations of COVID-19 (SARS-CoV-2): a review. Front Neurol. 2020;11:518. DOI 10.3389/fneur.2020.00518.